Safety of Risankizumab during Pregnancy in IBD

Noa Tsur; Ami Ben Ya'acov; Bella Ungar; Yulia Ron; Irit Avni-Biron; Hilla Reiss Mintz; Benjamin Koslowsky; Tali Mishael; Ariella Bar Gil Shitrit

doi:10.1093/ibd/izaf305

Safety of Risankizumab during Pregnancy in IBD

Inflamm Bowel Dis. 2026 Apr 1;32(4):817-819. doi: 10.1093/ibd/izaf305.

Authors

Noa Tsur¹, Ami Ben Ya'acov¹, Bella Ungar^{2

3}, Yulia Ron^{2

4}, Irit Avni-Biron^{2

5}, Hilla Reiss Mintz^{2

6}, Benjamin Koslowsky^{1

7}, Tali Mishael⁸, Ariella Bar Gil Shitrit^{1

7

9}

Affiliations

¹ IBD Mom Unit, Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
² Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Institute of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.
⁴ IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel.
⁵ IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
⁶ Maayanei Hayeshua Medical Center, Bnei Brak, Israel.
⁷ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
⁸ Obstetrics and Gynecology Division, Shaare Zedek Medical Center, Jerusalem, Israel.
⁹ The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.

No abstract available

Plain language summary

Our real-world data show that treatment with risankizumab in women with IBD does not confer additional risk for adverse obstetric or neonatal outcomes relative to anti-TNF or conventional therapies.